ERYTECH provides financial update for Q3 2013 Post author:admERY Post published:November 5, 2013 Post category:Newsroom ERYTECH announces today its cash position and its revenues for the third quarter of 2013. You Might Also Like ERYTECH Announces a Poster Presentation for TRYbeCA1 at the ASCO 2020 January 24, 2020 ERYTECH PHARMA receives € 7 Million from OSEO to lead the TEDAC personalized medicine project in cancer June 5, 2012 ERYTECH completes enrollment in its Phase III study in Acute Lymphoblastic Leukemia September 10, 2013
ERYTECH PHARMA receives € 7 Million from OSEO to lead the TEDAC personalized medicine project in cancer June 5, 2012
ERYTECH completes enrollment in its Phase III study in Acute Lymphoblastic Leukemia September 10, 2013
